The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move to safeguard its market share within the specialized pharmaceutical sector, Biogen has filed a lawsuit against Cipla Ltd for allegedly infringing on patents related to its drug, Spinraza. According to reports, the biotech giant claims that Cipla's actions violate intellectual property protections for the spinal muscular atrophy treatment. Furthermore, Biogen expanded its existing legal dispute with Somerset Therapeutics by adding three new patents covering specific treatment methods and dosing regimens, aiming to block generic versions that it asserts infringe upon its U.S. patents.
This legal escalation occurs as Biogen faces mounting pressure from competitors in the neurology market, where Spinraza remains a core revenue driver. Compared to industry peers, major biotech firms frequently utilize defensive patent litigation to extend market exclusivity and delay the entry of lower-cost generics from firms like Cipla. Per market data, such patent disputes in the pharmaceutical industry are common and often involve protracted legal battles that can last several years before reaching a definitive resolution or settlement.
Sign in to access this content
Sign InTraders should monitor BIIB stock levels, which stood at $196.58 (at close June 18, 2026), moving within a range of $193.2 to $200.99 based on recent price data. Looking ahead at the economic calendar, while there are no immediate sector-specific catalysts, broader market sentiment may be influenced by U.S. Initial Jobless Claims and the Philadelphia Fed Manufacturing Index on June 18, which could impact the performance of growth stocks in the healthcare space.